



(11) **EP 3 389 683 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**03.05.2023 Bulletin 2023/18**

(45) Date of publication and mention  
of the grant of the patent:  
**29.03.2023 Bulletin 2023/13**

(21) Application number: **16825728.5**

(22) Date of filing: **19.12.2016**

(51) International Patent Classification (IPC):  
**A61K 35/761** <sup>(2015.01)</sup> **A61K 35/768** <sup>(2015.01)</sup>  
**C07K 14/00** <sup>(2006.01)</sup> **A61K 39/00** <sup>(2006.01)</sup>  
**C07K 16/28** <sup>(2006.01)</sup> **A61P 35/00** <sup>(2006.01)</sup>  
**A61K 38/17** <sup>(2006.01)</sup>

(52) Cooperative Patent Classification (CPC):  
**A61K 35/761; A61K 35/768; A61K 38/1774;**  
**A61P 35/00; C07K 14/00; C07K 16/2803;**  
**A61K 2039/505; C07K 2317/622; C07K 2317/73**

(86) International application number:  
**PCT/EP2016/081818**

(87) International publication number:  
**WO 2017/103291 (22.06.2017 Gazette 2017/25)**

(54) **VIRUS ENCODING AN ANTI-TCR-COMPLEX ANTIBODY OR FRAGMENT**

ANTI-TCR-KOMPLEX-ANTIKÖRPER ODER -FRAGMENT CODIERENDER VIRUS

VIRUS CODANT POUR UN ANTICORPS ANTI-COMPLEXE DU TCR OU UN FRAGMENT DE  
CELUI-CI

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **17.12.2015 GB 201522334**  
**29.04.2016 GB 201607463**  
**10.10.2016 GB 201617207**  
**10.10.2016 GB 201617206**

(43) Date of publication of application:  
**24.10.2018 Bulletin 2018/43**

(73) Proprietor: **Akamis Bio Limited**  
**Abingdon, Oxfordshire OX14 3YS (GB)**

(72) Inventors:  
• **BROMLEY, Alice Claire Noel**  
**Abingdon**  
**Oxfordshire OX14 4SD (GB)**  
• **CHAMPION, Brian Robert**  
**Abingdon**  
**Oxfordshire OX14 4SD (GB)**

(74) Representative: **Sterling IP**  
**Orion House**  
**Bessemer Road**  
**Welwyn Garden City AL7 1HH (GB)**

(56) References cited:  
**WO-A1-2014/138314 WO-A1-2015/059303**  
**WO-A1-2015/097220 WO-A1-2015/155370**  
**WO-A1-2016/139463 WO-A1-2016/174200**

- **PAUL S ET AL: "TUMOR GENE THERAPY BY MVA-MEDIATED EXPRESSION OF T-CELL-STIMULATING ANTIBODIES", CANCER GENE THERAPY, APPLETON & LANGE, GB, vol. 9, no. 5, 1 May 2002 (2002-05-01), pages 470-477, XP001080563, ISSN: 0929-1903, DOI: 10.1038/SJ.CGT.7700461**
- **STEPHANE PAUL ET AL: "The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 51, no. 11-12, 1 December 2002 (2002-12-01), pages 645-654, XP055355169, Berlin/Heidelberg ISSN: 0340-7004, DOI: 10.1007/s00262-002-0314-2**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).